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AbsTrACT
Objective international studies report a decline in 
mortality following sT- elevation myocardial infarction 
(sTeMi). The extent to which the observed improvements 
in sTeMi survival are explained by temporal changes in 
patient characteristics and utilisation of treatments is 
unknown.
Methods cohort study using national registry data 
from the Myocardial ischaemia national audit Project 
between first January 2004 and 30th June 2013. 
232 353 survivors of hospitalisation with sTeMi as 
recorded in 247 hospitals in england and Wales. Flexible 
parametric survival modelling and causal mediation 
analysis were used to estimate the relative contribution 
of temporal changes in treatments and patient 
characteristics on improved sTeMi survival.
results Over the study period, unadjusted survival at 
6 months and 1 year improved by 0.9% and 1.0% on 
average per year (hr: 0.991, 95% ci: 0.988 to 0.994 
and hr: 0.990, 95% ci: 0.987 to 0.993, respectively). 
The uptake of primary percutaneous coronary 
intervention (Pci) (hr: 1.025, 95% ci: 1.021 to 1.028) 
and increased prescription of P2Y12 inhibitors (hr: 1.035, 
95% ci: 1.031 to 1.039) were significantly associated 
with improvements in 1- year survival. Primary Pci 
explained 16.8% (95% ci: 10.8% to 31.6%) and 13.2% 
(9.2% to 21.9%) of the temporal survival improvements 
at 6 months and 1 year, respectively, whereas P2Y12 
inhibitor prescription explained 5.3% (3.6% to 8.8%) 
of the temporal improvements at 6 months but not at 
1 year.
Conclusions For sTeMi in england and Wales, 
improvements in survival between 2004 and 2013 were 
significantly explained by the uptake of primary Pci 
and increased use of P2Y12 inhibitors at 6 months and 
primary Pci only at 1 year.
Trial registration number ncT03749694
InTrOduCTIOn
There has been a global decline in mortality and 
non- fatal complications following acute myocardial 
infarction.1 For ST- elevation myocardial infarction 
(STEMI), the adoption of new health technologies 
such as primary percutaneous coronary intervention 
(PPCI) as well as the availability of novel pharma-
cotherapies has been identified as driving improve-
ments in clinical outcomes.2 However, the extent 
to which population- based temporal improvements 
in outcomes from STEMI are due to the uptake of, 
say, PPCI compared with other guideline- indicated 
treatments or changes in patient characteristics is 
not known. Resolving the knowledge gap around 
the effectiveness of STEMI treatments on temporal 
outcomes could help future healthcare planning for 
developing countries with, or predicted to have, a 
high burden of cardiovascular disease.
Notably, there is a paucity of large- scale cohorts 
that are of sufficient duration to enable a detailed 
evaluation of the association of baseline risk and 
guideline- indicated therapies with temporal trends 
in STEMI mortality.3–5 Where there have been 
studies of treatments and outcomes for STEMI, 
analyses have quantified associations and not 
necessarily reported explanatory (causal) factors. 
The Myocardial Ischaemia National Audit Project 
(MINAP) is a whole country registry of hospitalised 
cases of acute coronary syndrome (ACS), repre-
senting all hospitals in a single health system (the 
National Health Service of England and Wales) 
with prospective collection of detailed informa-
tion about quality of care and clinical outcomes of 
patients for more than 15 years.6 7 Our objective 
was to investigate whether temporal improvements 
in survival were associated with changes in patients’ 
baseline clinical risk or use of guideline- indicated 
treatments for the management of STEMI, and 
to determine the extent to which associations 
explained the temporal improvements in survival.
MeThOds
data and patients
The analyses were based on data from MINAP, a 
comprehensive registry of ACS hospitalisations 
started in 2000 and mandated by the Department 
of Health in England and Wales.6 7 Data were 
collected prospectively at each hospital, elec-
tronically encrypted and transferred online to a 
central database. Data entry is subject to routine 
error checking and a mandatory annual data vali-
dation exercise. Patient- level data concerning 
demographics, cardiovascular risk factors, medical 
history and clinical characteristics at the time of 
hospitalisation were extracted from MINAP and (if 
applicable) date of death from linkage to the Office 
for National Statistics. Further details of MINAP 
have been published elsewhere.6 7 The diagnosis of 
STEMI was based on guidelines from the European 
Society of Cardiology (ESC), American College 
of Cardiology and American Heart Association, 
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Figure 1 Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) diagram showing the derivation of the 
analytical cohort from the Myocardial Ischaemia National Audit Project 
dataset.
and determined at local level by the attending Consultant on 
discharge from hospital.8
The analytical cohort (n=232 353) was drawn from 272 263 
patients with STEMI admitted to one of 247 hospitals between 
first January 2004 and 30 June 2013 (figure 1). For multiple 
admissions, we used the earliest record. As discharge medica-
tion was a key exposure, we excluded 23 504 (8.6%) who died 
in hospital; 16 406 (6.0%) patients with missing mortality 
data were also excluded. The primary outcome was all- cause 
mortality at 1 year following discharge from hospital. For care 
interventions, patients were classified as ineligible if a treatment 
was contraindicated, not indicated, not applicable, if the patient 
declined treatment as recorded in MINAP or if the admission 
preceded the inclusion of the treatment in guidelines (online 
supplementary eTable 1).
statistical analyses
Baseline characteristics were described using numbers and 
percentages for categorical data and means and SD or medians 
and interquartile ranges for normally and non- normally distrib-
uted continuous variables. Temporal trends of patient and 
treatment characteristics were summarised by comparing data 
from the start of the study (2004–2005) to the end of the study 
(2012–2013) using χ2 tests, t- tests and Wilcoxon rank sum tests.
Royston- Parmar flexible parametric survival models9 were 
fitted to explore the association between temporal changes in 
patient demographics (age, sex, socioeconomic deprivation 
(Index of Multiple Deprivation score), comorbidities and risk 
factors (diabetes, hypercholesterolaemia, hypertension, smoking 
status, asthma/chronic obstructive pulmonary disease, chronic 
renal failure, chronic cardiac failure, cerebrovascular disease, 
peripheral vascular disease, angina, previous myocardial infarc-
tion, PCI and coronary artery bypass graft surgery), pharma-
cological treatments (secondary prevention pharmacotherapies 
prescribed at hospital discharge: aspirin, statins, P2Y12 inhibi-
tors, ACE inhibitors (ACEi)/ARBs and β-blockers), cardiac 
rehabilitation and reperfusion strategy (defined as receipt of 
PPCI) with temporal changes in 1- year survival from hospital 
discharge. Flexible parametric survival models were selected 
in favour of Cox regression models to overcome violation of 
the proportional hazards assumption. Improvements in model 
fit at each stage were determined by minimising the Akaike 
information criterion (AIC) and Bayesian information criterion 
(BIC) (online supplementary eTable 2). The scale (proportional 
hazards, proportional odds or normal) and complexity (number 
of degrees of freedom) for flexible parametric survival models 
were checked on the full multivariable model for each imputa-
tion. The baseline hazard on the normal scale with five degrees 
of freedom produced the optimal model through minimisation 
of the AIC and BIC (online supplementary eTable 2).
Initially, to determine the overall temporal trend in 1- year 
survival, an unadjusted model comprising only the year of admis-
sion was fitted. Subsequently, to determine the impact of patient 
demographics, PPCI, comorbidities and risk factors, aspirin 
at discharge, statin at discharge, P2Y12 inhibitors at discharge, 
ACEi/ARBs at discharge, β-blockers at discharge and cardiac 
rehabilitation on the temporal trend in survival, each of these 
factors were added individually to the univariate year model. 
These models were then adjusted for age, sex and deprivation to 
form the primary analysis.
Secondary analyses included; a full model including all of the 
explanatory and adjustment variables stated above. This strategy 
allowed the influence of each factor on the temporal survival 
trend to be assessed in both an unadjusted and adjusted manner. 
To confirm that the identified factors had an association with 
survival trends, two flexible parametric survival models were fit, 
one including only the subset of variables found to have an influ-
ence on the survival trends (model A) and the other including 
only the subset variables found not to have an influence on 
survival trends (model B).
A causal mediation analysis was conducted to determine the 
relative contribution of patient and treatment variables on the 
survival trend. This analysis allowed the assessment of poten-
tial causal pathways that linked year of admission to temporal 
improvements in STEMI survival, such as through changes in 
clinical factors or therapeutic strategies, beyond simple point 
estimates. The magnitude of the contribution of the mediating 
variables was adjusted for confounding variables (online supple-
mentary section 2) and presented as proportions.
To mitigate potential bias caused by missing data, we used 
multiple imputation by chained equations to create 10 datasets 
from 20 iterations, of which the resultant model estimates for 
each were combined using Rubin’s rules (Section 3, eTable three 
in the Supplement for the imputation strategy). As a secondary 
outcome, we repeated the above analytical methods for temporal 
changes in 6- month survival. All tests were two- sided, and statis-
tical significance was considered p<0.05. Statistical analyses 
were performed in Stata V.14 (http://www. stata. com/) and R 
V.1.2 (https:// cran. r- project. org/ bin/ windows/ base/).
Patient involvement
This study did not involve patients/service users/carers/lay people 
in its design or for the development of outcome measures.
resulTs
Of the analytical cohort (n=2 32 353), 72.0% (n=1 66 690) 
were men, and the median age was 64.6 (IQR 55.0–75.0) 
years. A high proportion had hypertension (37.9%, n=87 990), 
a family history of coronary heart disease (25.7%, n=59 709) 
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Table 1 Patient characteristics, by year of hospitalisation
Variable
2004–2013
n=2 32 353 (Total cohort)
2004–2005
n=42,799 (18.4% of the 
cohort)
2012–2013
n=37,081 (16.0% of 
cohort)
difference between 
2004–2005 and 2012–2013 
(95% CI) P value
Age (years) Median (IQR) 64.6 (55.0–75.0) 65.3 (55.8–74.9) 64.0 (54.5–74.9) 1.30 (1.04 to 1.56) <0.001
Sex (male) N (%) 166 690 (72.0) 30 332 (71.2) 26 590 (72.2) 0.93 (0.30 to 1.56) 0.004
Deprivation (IMD score) Median (IQR) 18.4 (10.5–32.2) 18.7 (10.6–32.6) 18.4 (10.5–32.1) 0.37 (0.08 to 0.66) 0.012
Systolic blood pressure (mm Hg) Mean (SD) 136.5 (28.2) 139.9 (29.2) 132.8 (26.9) −7.18 (−7.61 to −6.74) <0.001
Heart rate (beats per min) Mean (SD) 77.9 (20.8) 77.1 (21.4) 77.9 (19.4) 0.83 (0.51 to 1.14) <0.001
Total cholesterol (mg/dL) Median (IQR) 5.1 (4.2–6.0) 5.4 (4.5–6.3) 4.9 (4.0–5.8) 0.50 (0.47 to 0.53) <0.001
Creatinine (mg/dL) Median (IQR) 87.0 (74.0–104.0) 101.0 (90.0–116.0) 82.0 (70.0–99.0) 19.0 (17.3 to 20.7) <0.001
Ejection fraction <50% N (%) 38 634 (49.3) 1753 (53.2) 9598 (49.5) −3.72 (−5.56 to −1.88) <0.001
Medical history   
  Previous diabetes N (%) 29 083 (12.5) 5265 (12.3) 5158 (13.9) 1.61 (1.14 to 2.08) <0.001
  Current or ex- smoker N (%) 143 508 (68.1) 27 098 (69.9) 22 338 (66.0) 3.93 (−4.61 to 3.25) <0.001
  Family history of CHD N (%) 59 709 (25.7) 4633 (10.8) 10 249 (27.6) 16.8 1 (16.27 to 17.34) <0.001
  Hypertension N (%) 87 990 (37.9) 15 938 (37.2) 13 960 (37.7) 0.41 (−0.26 to 1.08) 0.235
  Previous MI N (%) 26 892 (11.6) 5525 (12.9) 4012 (10.8) −2.09 (−2.54 to −1.64) <0.001
  Previous angina N (%) 31 060 (13.4) 7050 (16.5) 4036 (10.9) −5.59 (−6.06 to −5.11) <0.001
  Peripheral vascular disease N (%) 5868 (2.5) 1168 (2.7) 950 (2.7) −0.17 (−0.39 to 0.06) 0.143
  Cerebrovascular disease N (%) 10 415 (4.5) 1896 (4.4) 1612 (4.4) −0.08 (−0.37 to 0.20) 0.569
  COPD or asthma N (%) 23 404 (10.1) 4444 (10.4) 3745 (10.1) −0.28 (−0.71 to 0.14) 0.187
  Chronic renal failure N (%) 4410 (1.9) 576 (1.4) 793 (2.1) 0.79 (0.61 to 0.98) <0.001
  Congestive cardiac failure N (%) 3593 (1.6) 762 (1.8) 529 (1.4) −0.35 (−0.53 to −0.18) <0.001
  Previous PCI N (%) 12 006 (5.2) 1488 (3.5) 2318 (6.3) 2.77 (2.47 to 3.08) <0.001
  Previous CABG N (%) 5217 (2.3) 921 (2.2) 840 (2.3) 0.11 (−0.09 to 0.32) 0.276
Admission diagnosis   
  ACS or probable MI N (%) 217 563 (93.6) 40 231 (94.0) 35 270 (95.1) 1.12 (0.80 to 1.43) <0.001
  Chest pain unknown cause N (%) 6810 (2.9) 1313 (3.1) 797 (2.2) −0.92 (−1.14 to 0.70) <0.001
  Other N (%) 7976 (3.4) 1255 (2.9) 1014 (2.7) −0.20 (−0.43 to 0.03) 0.093
Preadmission medications*   
  Aspirin N (%) 146 742 (64.4) 26 121 (62.9) 25 229 (68.8) 5.88 (5.22 to 6.55) <0.001
  β-blocker N (%) 37 199 (22.3) 4294 (32.2) 6097 (20.3) −11.94 (−12.85 to −11.0) <0.001
  Statin N (%) 54 151 (31.2) 5008 (37.7) 9654 (30.2) −7.47 (−8.44 to −6.50) <0.001
  ACEi or ARBs N (%) 45 897 (27.5) 4264 (32.2) 8424 (28.0) −4.20 (−5.14 to −3.25) <0.001
  P2Y12 inhibitor N (%) 13 136 (14.2) – 4566 (14.8) –
  Warfarin N (%) 6891 (3.7) 1558 (4.6) 1060 (3.6) −1.00 (−1.31 to −0.69) <0.001
Discharge medications*   
  Aspirin N (%) 186 098 (98.8) 35 753 (98.1) 30 197 (99.2) 1.13 (0.96 to 1.30) <0.001
  β-blocker N (%) 165 472 (95.7) 30 375 (94.1) 28 207 (97.5) 3.40 (3.09 to 3.72) <0.001
  Statin N (%) 185 710 (98.1) 35 708 (97.3) 30 029 (98.8) 1.46 (1.26 to 1.67) <0.001
  ACEi or ARB N (%) 173 303 (95.3) 32 616 (93.1) 28 567 (97.3) 4.16 (3.83 to 4.48) <0.001
  P2Y12 inhibitor N (%) 89 676 (96.7) 190 (94.5) 28 694 (97.6) 3.05 (−0.10 to 6.20) 0.005
  Aldosterone antagonist N (%) 7296 (12.6) 0 (0) 3031 (15.8) – –
Reperfusion strategy*   
  PPCI N (%) 83 627 (39.6) 148 (2.1) 26 799 (80.2) 78.15 (77.61 to 78.69) <0.001
  Thrombolysis N (%) 83 800 (39.6) 30 220 (81.1) 1218 (15.6) −65.54 (−66.44 to −64.65) <0.001
  CABG N (%) 1638 (0.8) 276 (3.8) 247 (3.6) 0.17 (−0.79 to 0.45) 0.593
  None† N (%) 42 354 (20.0) 6955 (18.6) 6275 (18.2) −0.40 (−1.00 to 0.13) 0.129
Cardiac rehabilitation N (%) 182 575 (92.4) 33 933 (89.8) 30 387 (94.3) 4.44 (4.05 to 4.84) <0.001
GRACE risk score category
  Lowest (<70) N (%) 5034 (5.0) 30 (5.6) 1099 (4.7) −0.84 (−2.79 to 1.11) 0.362
  Low (70-87) N (%) 11 541 (11.4) 61 (11.3) 2654 (11.4) 0.08 (−2.61 to 2.78) 0.952
  Intermediate to high (≥88) N (%) 84 509 (83.6) 450 (83.2) 19 612 (83.9) 0.76 (−2.43 to 3.95) 0.635
Crude mortality   
  30 days N (%) 5517 (2.4) 1046 (2.4) 836 (2.3) −0.18 (−0.40 to 0.02) 0.078
  6 months N (%) 12 143 (5.2) 2347 (5.5) 1703 (4.6) −0.89 (−1.19 to −0.59) <0.001
  1 year N (%) 16 239 (7.0) 3221 (7.5) 2090 (5.6) −1.89 (−2.23 to −1.55) <0.001
*Only patients eligible (eligibility criteria definition used given in online supplementary section 1) to receive treatments were included in the denominator of the complete cases.
†Reasons for non- receipt of PPCI/thrombolysis included: (1) ineligible ECG (25.2% (n=10,678)), (2) too late (32.8% (n=13,878)), (3) risk of haemorrhage (6.7% (n=2,837)), (4) uncontrolled hypertension (0.5% (n=209)), 
(5) administrative failure (1.7% (n=711)), (6) elective decision (15.4% (n=6,521)), (7) patient refused treatment (1.4% (n=570)) and (8) other (16.4% (n=6,950)).
ACEi, ACE inhibitor; ACS, acute coronary syndrome; ARBs, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; GRACE, Global 
Registry of Acute Coronary Events; IMD, index of multiple deprivation; MI, myocardial infarction; PCI, percutaneous coronary intervention; PPCI, primary percutaneous coronary intervention.
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Figure 2 Temporal trends of comorbidities and risk factors, per 
month, 2004–2013.
Figure 3 Use of pharmacological therapies at hospital discharge, 
thrombolysis and primary percutaneous coronary intervention per 
month, 2004–2013.
or were current or ex- smokers (68.1%, n=1 43 508) (table 1). 
There were 12 143 (5.2%) deaths at 6 months and 16 239 (7.0%) 
deaths at 1 year after hospital discharge.
Temporal trends in clinical characteristics
Over the study period, the proportion of STEMI who had a 
previous myocardial infarction (12.9 vs 10.8%), angina (16.5 
vs 10.9%) and were current or ex- smokers (69.9 vs 66.0%) 
decreased (all p<0.001), while the proportion of patients with 
diabetes (12.3 vs 13.9%), chronic renal failure (1.4 vs 2.1%) and 
previous PCI (3.5 vs 6.3%) increased (all p<0.001) (table 1 and 
figure 2). The proportion with a reduced ejection fraction (EF 
<50%) decreased from 53.2% in 2004-05 to 49.5% in 2012–
2013 (table 1).
Temporal trends in guideline-indicated treatments
The use of the secondary prevention pharmacotherapies at 
hospital discharge was high (>90% for all five drugs), and 
increased over the study period: aspirin increased from 98.1% 
to 99.2% (difference 1.1%, 95% CI: 1.0% to 1.3%), β-blockers 
from 94.1% to 97.5% (difference 3.4%, 3.1% to 3.7%), statins 
from 97.3% to 98.8% (difference 1.5%, 1.3% to 1.7%) and 
ACEi/ARBs from 93.1% to 97.3% (difference 4.2%, 3.8% 
to 4.5%) (table 1 and figure 3). Overall, 39.6% (n=83 627) 
received PPCI and 39.6% (n=83 800) received thrombolysis. 
The majority (n=30 220, 81.1%) of those hospitalised in 2004–
2005 received thrombolysis, and the majority of those hospital-
ised in the years 2012–13 received PPCI (n=26 799, 80.2%).
Association between changing risk profile and improved 
outcomes
One-year survival
Unadjusted 1- year survival improved by 1.0% per year, on 
average, over the study period (HR: 0.990, 95% CI: 0.987 
to 0.993) (table 2 and figure 4). This temporal improvement 
remained after adjustment for age, sex and deprivation (HR: 
0.990, 95% CI, 0.987 to 0.993), cardiac rehabilitation (HR: 
0.989, 95% CI: 0.986 to 0.992) and comorbidities and risk 
factors (HR: 0.993, 95% CI, 0.990 to 0.996). However, the 
direction of association was reversed after adjustment for PPCI 
(HR: 1.025, 95% CI: 1.021 to 1.028), and there was no temporal 
trend after adjusting for pharmacotherapies (HR: 0.998, 95% 
CI, 0.994 to 1.002). Individual assessments of the pharmaco-
therapies found that the temporal improvement remained after 
adjustment for aspirin (HR: 0.988, 95% CI: 0.985 to 0.991), 
statins (HR: 0.987, 95% CI, 0.984 to 0.989), β-blockers (HR, 
0.993; 95% CI: 0.990 to 0.996), ACEi/ARBs (HR: 0.989, 95% 
CI: 0.986 to 0.992), and only after adjustment of P2Y12 inhibi-
tors (HR: 1.035, 95% CI: 1.031 to 1.039) was the direction of 
association reversed. In the fully adjusted model, the direction of 
association was reversed (HR: 1.006, 95% CI: 1.001 to 1.011). 
Comparing a model including only those factors which influ-
enced survival trends with a model including only those factors 
which did not (model A vs model B, table 3) confirmed that 
model A variables accounted for improved survival (HR: 1.061, 
95% CI: 1.057 to 1.065), whereas the overall temporal trend 
in survival remained after adjustments made in model B (HR: 
0.990, 95% CI: 0.986 to 0.993) (table 3).
six-month survival
Unadjusted 6- month survival improved by 0.9% per year, on 
average, over the study period (HR: 0.991, 95% CI: 0.988 
to 0.994) (table 2 and figure 4). This temporal improvement 
remained after adjustment for age, sex and deprivation (HR: 
0.991, 95% CI: 0.988 to 0.994), cardiac rehabilitation (HR: 
0.990, 95% CI: 0.987 to 0.993) and comorbidities and risk 
factors (HR: 0.994, 95% CI: 0.991 to 0.997). However, the 
direction of association was reversed after adjustment for PPCI 
(HR: 1.025, 95% CI: 1.021 to 1.029) and there was no temporal 
trend after adjusting for pharmacotherapies (HR: 0.998, 95% 
CI: 0.993 to 1.002). Individual assessments of the pharmaco-
therapies showed that the temporal improvement remained 
after adjusting for aspirin (HR: 0.988, 95% CI: 0.985 to 0.992), 
statins (HR: 0.987, 95% CI: 0.984 to 0.990), β-blockers (HR: 
0.994, 95% CI: 0.991 to 0.998), ACEi/ARBs (HR: 0.991, 95% 
CI: 0.987 to 0.993). Only after adjustment for receipt of P2Y12 
inhibitors was the direction of association reversed (HR: 1.040, 
95% CI: 1.037 to 1.045). In the fully adjusted model, the direc-
tion of association was reversed (HR: 1.006, 95% CI: 1.001 
to 1.011). Comparing a model including only the factors that 
influenced survival trends with a model including only those 
factors that did not (model A vs model B, table 3) confirmed that 
model A variables accounted for improved survival (HR 1.066, 
95% CI 1.061 to 1.071), whereas the overall temporal trend 
in survival remained after adjustments made in model B (HR: 
0.990, 95% CI: 0.986 to 0.993) (table 3). Given that the number 
of people with prior use of statin at presentation of STEMI 
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Table 2 Impact of patient and treatment factors on temporal trends in 6- month and 1- year survival from hospital discharge between 2004 and 
2013, for unadjusted and adjusted flexible parametric survival models
Model number Variables included
six months
P values
One year
P valueshr (95% CI) hr (95% CI)
Model 1 Year 0.991 (0.988–0.994) <0.001 0.990 (0.987–0.993) <0.001
Year +
Model 2 Age, sex, IMD 0.991 (0.988 to 0.994) <0.001 0.990 (0.987 to 0.993) <0.001
Model 3 PPCI 1.025 (1.021 to 1.029) <0.001 1.025 (1.021 to 1.028) <0.001
Model 4 Comorbidities and risk factors 0.994 (0.991 to 0.997) <0.001 0.993 (0.990 to 0.996) <0.001
Model 5 Five discharge drugs 0.998 (0.993 to 1.002) 0.404 0.998 (0.994 to 1.002) 0.379
Model 6 Aspirin 0.988 (0.985 to 0.992) <0.001 0.988 (0.985 to 0.991) <0.001
Model 7 Statins 0.987 (0.984 to 0.990) <0.001 0.987 (0.984 to 0.989) <0.001
Model 8 P2Y12 inhibitors 1.040 (1.037 to 1.045) <0.001 1.035 (1.031 to 1.039) <0.001
Model 9 ACEi/ARBs 0.991 (0.987 to 0.993) <0.001 0.989 (0.986 to 0.992) <0.001
Model 10 β-blockers 0.994 (0.991 to 0.998) <0.001 0.993 (0.990 to 0.996) <0.001
Model 11 Cardiac rehabilitation 0.990 (0.987 to 0.993) <0.001 0.989 (0.986 to 0.992) <0.001
Year +age + sex+IMD +
Model 12 PPCI 1.014 (1.010 to 1.018) <0.001 1.013 (1.009 to 1.016) <0.001
Model 13 Comorbidities and risk factors 0.992 (0.989 to 0.996) <0.001 0.991 (0.988 to 0.994) <0.001
Model 14 Five discharge drugs 0.993 (0.988 to 0.988) 0.003 0.993 (0.989 to 0.997) 0.001
Model 15 Aspirin 0.987 (0.984 to 0.991) <0.001 0.987 (0.984 to 0.990) <0.001
Model 16 Statins 0.968 (0.983 to 0.990) <0.001 0.986 (0.982 to 0.989) <0.001
Model 17 P2Y12 inhibitors 1.040 (1.035 to 1.044) <0.001 1.034 (1.030 to 1.038) <0.001
Model 18 ACEi/ARBs 0.990 (0.986 to 0.993) <0.001 0.988 (0.985 to 0.992) <0.001
Model 19 β-blockers 0.994 (0.991 to 0.998) 0.001 0.993 (0.990 to 0.996) <0.001
Model 20 Cardiac rehabilitation 0.991 (0.987 to 0.994) <0.001 0.989 (0.986 to 0.992) <0.001
Model 21 Year +age + sex+IMD + PPCI+comorbidities and risk 
factors+Aspirin + Statins+P2Y12 inhibitors+ACEi/ARBs + β-blockers+cardiac rehabilitation
1.006 (1.001 to 1.011) 0.014 1.006 (1.001 to 1.011) 0.013
ACEi, ACE inhibitor; ARBs, angiotensin receptor blocker; IMD, Index of Multiple Deprivation; PPCI, primary percutaneous coronary intervention.
Figure 4 Crude all- cause mortality at 6- month and 1- year following 
hospital discharge, per month, 2004–2013.
declined over the study period, we conducted a sensitivity anal-
yses stratified according to prior statin use in which our findings 
were substantiated (online supplementary eTables 4 and 5).
Causal mediation analysis
The uptake of PPCI explained 13.2% (95% CI: 9.2% to 21.9%; 
average across the 10 imputed datasets) of the 1- year and 16.8% 
(95% CI: 10.8% to 31.6%) of the 6- month survival improve-
ments (online supplementary eTables 6 and 7). The increased 
prescription of P2Y12 inhibitors at hospital discharge explained 
5.3% (95% CI: 3.6% to 8.8%) of the improvement at 6 months, 
but not at 1 year (online supplementary eTables 6 and 7). A sensi-
tivity analysis including in- hospital deaths was carried out and 
the results were consistent with the main findings (online supple-
mentary eTables 8 and 9).
dIsCussIOn
In this national cohort study of the management and outcome of 
nearly a quarter of a million patients hospitalised with STEMI, 
we found that temporal improvements in 1- year survival 
between 2004 and 2013 were associated with the uptake of 
PPCI and increased prescription of P2Y12 inhibitors at hospital 
discharge. Similar findings were observed for temporal improve-
ments in 6- month survival. At the end of the study, the use of 
guideline- indicated therapies for STEMI was high, such that over 
three- quarters of patients with STEMI received PPCI, and the 
prescription of evidence- based pharmacotherapies reached more 
than 95%. While the majority of treatment and patient- related 
factors studied were significantly associated with 6- month and 
1- year survival, it was only temporal trends in PPCI and P2Y12 
inhibitors at hospital discharge that significantly explained the 
temporal trend in survival.
The association between guideline recommended care and 
improved survival after myocardial infarction is recognised and 
supported by robust evidence from randomised clinical trials.10 
For STEMI, PPCI has been shown to be associated with a decline 
in mortality,11–13 as has the use of antithrombotic and secondary 
prevention medications.3 4 14 15 While others have investigated 
whether these or other factors are associated with the decline in 
mortality over time,3–5 to our knowledge this is the largest study 
to date and first investigation using causal medication analysis 
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Table 3 Temporal trends by year in overall survival following hospital discharge between 2004 and 2013 for unadjusted and adjusted flexible 
parametric survival models (comparing model builds for model including only explanatory variables concluded to have an influence improvements in 
survival trends (model a) with model containing only variables concluded not to influence improvements in survival trends (model B))
six months One year
hr (95% CI) P value hr (95% CI) P value
Model A
  Unadjusted yearly time trend 0.991 (0.988 to 0.994) <0.001 0.990 (0.987 to 0.993) <0.001
  Yearly time trend adjusted for
  P2Y12 inhibitors at discharge 1.041 (1.037 to 1.045) <0.001 1.035 (1.031 to 1.039) <0.001
  P2Y12 inhibitors at discharge and PPCI 1.066 (1.061 to 1.071) <0.001 1.061 (1.057 to 1.065) <0.001
Model B
  Unadjusted yearly time trend 0.991 (0.988 to 0.994) <0.001 0.990 (0.987 to 0.993) <0.001
  Yearly time trend adjusted for
  Age, sex and IMD 0.991 (0.988 to 0.994) <0.001 0.990 (0.987 to 0.993) <0.001
  Age, sex, IMD and pharmacological therapies at discharge (aspirin, 
statins, β-blockers and ACEi/ARBs)
0.988 (0.984 to 0.992) <0.001 0.988 (0.985 to 0.991) <0.001
  Age, sex, IMD, pharmacological therapies at discharge (aspirin, statins, 
β-blockers and ACEi/ARBs) and comorbidities and risk factors
0.990 (0.987 to 0.994) <0.001 0.990 (0.987 to 0.994) <0.001
  Age, sex, IMD, pharmacological therapies at discharge (aspirin, statins, 
β-blockers and ACEi/ARBs), comorbidities and risk factors, and cardiac 
rehabilitation
0.990 (0.986 to 0.993) <0.001 0.990 (0.986 to 0.993) <0.001
ACEi, ACE inhibitor; ARBs, angiotensin receptor blocker; IMD, Index of Multiple Deprivation; PPCI, primary percutaneous coronary intervention.
to determine the relative contribution of factors on survival 
improvements in STEMI.
Our findings support and extend the existing literature.3–5 A 
recent study of 105 674 patients with STEMI recorded in the 
Swedish Web- System for Enhancement and Development of 
Evidence- Based Care in Heart Disease Evaluated According to 
Recommended Therapies registry found that changes in reper-
fusion and PPCI were each associated with improved in- hospital 
outcomes, whereas an increase in the prescription of discharge 
medications was associated with improved outcomes at 1 year. 
Our study builds on this, finding that the nationwide introduc-
tion of PPCI explained over one- tenth of the improvements in 
1- year survival for STEMI.
We found no significant mediation effect for improvements in 
1- year survival by increased prescription of P2Y12 inhibitors at 
hospital discharge. By contrast, a significant effect was identified 
for survival improvements at 6 months. Debate remains as to the 
most appropriate duration of dual antiplatelet therapy following 
myocardial infarction16–18 and in the UK variation exists as to 
whether this is from 3 to 12 months or longer.19 Thus, it is 
possible that persistence with therapy influenced the duration 
of the causal effect. Alternatively, it may be that a second anti-
platelet agent following STEMI has limited benefit for longer- 
term all- cause mortality.18
The finding that the uptake of P2Y12 inhibitors and PPCI 
significantly explained the temporal trends in survival is not 
surprising. P2Y12 inhibitors are indicated with a Class I recom-
mendation and Level A evidence10 for all STEMI before, or at the 
time of PPCI. As such, one would expect a moderating relation-
ship between PPCI and P2Y12 inhibitors. Yet, the uptake of PPCI 
and increased prescription of P2Y12 inhibitors did not explain 
all of the improvements in survival. Earlier research found that 
organisational factors, as well as national and local infrastructure 
are key elements in the delivery of a STEMI service and, there-
fore, clinical outcomes.2
This study has wider implications for international cardiovas-
cular health. In line with the WHO Global Action Plan for non- 
communicable disease, we have identified factors including and 
beyond PPCI that are associated with improved survival over 
time for patients with STEMI—therefore helping identify where 
in a healthcare system the provision of essential treatments is 
required to reduce premature death. Furthermore, our results 
may be extrapolated to other developed and developing coun-
tries which lag behind Northern Europe and North America in 
their provision of care and where greater gains in cardiovascular 
health maybe realised.20 21
MINAP is the largest whole- country, single- health- system, 
prospective observational cohort of the quality of care and clin-
ical outcomes for ACS. It is designed to be representative of the 
management of ACS and has standardised criteria for defining 
case mix and treatments. To our knowledge, this study is the 
first to quantify the relative contribution mediators of temporal 
improvements in survival for STEMI. However, our study has 
limitations. (1) We were reliant on the accurate recording of 
data in MINAP. (2) MINAP collects the majority, but not all 
cases of STEMI in England and Wales. (3) Missing data could 
have biassed our estimates; to mitigate this we studied the 
nature of the missing data and used imputation algorithms. (4) 
Other factors beyond the hospital stay (such as drug adherence 
and compliance, and primary care visits) may have influenced 
temporal changes in survival. (5) We studied all- cause mortality, 
when non- cardiovascular deaths may not be attributable to 
temporal improvements in STEMI care.22 (6) Given that the 
determined mediators did not fully explain the survival improve-
ments implies unmeasured mediators exist out with MINAP data 
fields. (7) MINAP lacks information on temporal change in stent 
platforms, that is, shift from bare metal stents to first- generation 
and second- generation drug eluting stents. (8) Door- to- balloon 
and total ischaemic times were not investigated as potential 
mediators due to poor recording of this information within our 
MINAP extract.
COnClusIOn
Among 232 353 patients hospitalised with STEMI in England 
and Wales, improvements in all- cause mortality between 2004 
and 2013 were significantly associated with, and explained by, 
the national uptake of PPCI and increased prescription of P2Y12 
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inhibitors, and not entirely related to changes in comorbidities 
or increased use of other pharmacological therapies.
Key messages
What was already known on this subject?
 ► Temporal improvements in survival following ST- elevation 
Myocardial Infarction (STEMI) have been observed and the 
improvements have been attributed to adoption of new 
health technologies such as primary percutaneous coronary 
intervention (PPCI) as well as the availability of novel 
pharmacotherapies. However, the relative contributions 
of temporal improvements in treatments and patient 
characteristics on improved STEMI survival are unknown.
What might this study add?
 ► While the majority of treatment and patient- related factors 
studied were significantly associated with STEMI survival, 
it was only temporal improvements in P2Y12 inhibitors 
prescription and national uptake of PPCI that significantly 
explained the temporal trend in STEMI survival observed 
between 2004 and 2013.
how might this impact on clinical practice?
 ► Identifying factors associated with improved survival 
over time for patients with STEMI helps identify where in 
healthcare systems the provision of essential treatments 
is required to reduce premature death from cardiovascular 
disease.
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